We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noninvasive Prenatal Test Screens Blood for Chromosomal Abnormalities

By LabMedica International staff writers
Posted on 27 Feb 2013
Physicians will have access to a new noninvasive prenatal test, which uses cell-free fetal DNA in circulating maternal blood.

The test, called Panorama, uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome). More...
Panorama can be used as early as the ninth week of pregnancy.

Quest Diagnostics (Madison, NJ, USA), a diagnostic information services company, and Natera (San Carlos, CA, USA), an innovator in prenatal genetic testing, announced that Quest Diagnostics will offer physicians access to Panorama, the new noninvasive prenatal test developed by Natera.

Physician will be able to forward specimens for testing to Natera's Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Carlos (CA, USA), which developed and validated the lab-developed Panorama test. The test will be made available to physician clients of Quest Diagnostics in certain regions in March and nationwide in the United States in April 2013.

In December 2012, the American Congress of Obstetricians and Gynecologists (ACOG) issued a medical opinion stating that cell-free fetal DNA testing is one option that can be used as a primary screening test in women at increased risk of aneuploidy. It may also be offered as a follow-up test for women with a positive first-trimester or second-trimester screening test result.

A “low risk” Panorama test result indicates a lower likelihood that a pregnancy is affected. With this information, a woman may consider, in consultation with her physician and results of other medical assessments, whether to pursue or forgo invasive diagnostic testing, which carries a slight risk of miscarriage. A “low risk” Panorama result does not guarantee an unaffected pregnancy.

"Cell-free fetal DNA testing is a significant advance in prenatal screening," said Charles Strom, MD, PhD, senior medical director, genetics, Quest Diagnostics Nichols Institute. "By offering physicians and women access to Panorama, Quest Diagnostics is delivering on its commitment to provide clinically important innovations aligned with guideline-based care."

Natera is a leading genetic testing company that has developed a proprietary bioinformatics-based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from minute quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos (CA, USA) providing a host of preconception and prenatal genetic testing services.

Related Links:
Quest Diagnostics
Natera




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.